NAS:CNCR

Range Cancer Therapeutics ETF

$ 15.16 0.2 ( +1.34%) 03:36 PM EST
PE Ratio:
31.84
PB Ratio:
1.82
Volume:
3.52K
Dividend Yield %:
0
Last Holding update 2024-10-25 75 Stocks (0 new)
Value $13.00 Mil Turnover 0 %
Top Holdings: SMMT(3.83%) GERN(3.81%) ELVN(2.66%) ACRV(2.63%) NRIX(2.52%)
Portfolio Report
Registrant: Range Cancer Therapeutics ETF
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Performance Chart Fundamental Charts Technical Indicators Gurus Trades Top Holdings Sector Breakdowns Holding History Back to Top

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Key Statistics

Name Value
Day's Open ($) 15.0086
Day's Range ($) 15.0086 - 15.16
Day's Volume 3,522
52-Week Range ($) 9.52 - 17.96
Beta 0.94
Volatility 38.76
14-Day RSI 50.18
14-Day ATR ($) 0.32395
20-Day SMA ($) 14.916

Fundamental Data

Name Value
Market Cap (Mil $) 12.595
Shares Outstanding (Mil) 0.83
PE Ratio 31.84
PE Ratio (10y Range) 12.64 - 31.84
PE Ratio (10y Median) 20.85
PB Ratio 1.82
PB Ratio (10y Range) 1.82 - 5.84
PB Ratio (10y Median) 4.26

Dividend Data

Name Value
Dividends per Share (TTM) ($) -
Dividend Yield % -
Dividend Yield % (10y Range) 0.4 - 14.16
Dividend Yield % (10y Median) 1.31
Next Dividend Payment Date
Dividend Frequency -

CNCR Range Cancer Therapeutics ETF Fundamental Charts

Historical TTM Price-to-Earnings for CNCR Range Cancer Therapeutics ETF

Historical TTM Price-to-Earnings without NRI for CNCR Range Cancer Therapeutics ETF

Historical Price-to-Book Ratio for CNCR Range Cancer Therapeutics ETF

Historical Dividend Yields for CNCR Range Cancer Therapeutics ETF

CNCR Range Cancer Therapeutics ETF Technical Indicators

Moving Average

Momentum

Gurus Latest Trades with NAS:CNCR

No Available Data

NAS:CNCR is held by these investors

No Available Data
Range Cancer Therapeutics ETF Top Holdings of 2024-08-31 View Full List
Ticker
Company
Shares
Value ($1000)
Shares Change %
Weighting %
Trade Impact %
% of Shares outstanding
3M Change %
YTD Change %
Market Cap $Mil
Industry
SMMT 		Summit Therapeutics Inc
39,094
507.440
-19.31%
3.830
-0.49%
0.010
+103.59%
+681.23%
15036.568
Biotechnology
GERN 		Geron Corp
106,113
504.040
-19.31%
3.810
-0.55%
0.020
-6.43%
+100.00%
2543.797
Biotechnology
ELVN 		Enliven Therapeutics Inc
16,094
352.140
-19.30%
2.660
-0.53%
0.030
+26.68%
+102.38%
1323.114
Biotechnology
ACRV 		Acrivon Therapeutics Inc
36,627
347.590
-19.31%
2.630
-0.41%
0.120
+6.10%
+59.15%
242.512
Biotechnology
NRIX 		Nurix Therapeutics Inc
13,230
333.400
-19.28%
2.520
-0.30%
0.020
+22.70%
+146.41%
1801.367
Biotechnology
ITOS 		ITeos Therapeutics Inc
17,308
291.640
-19.30%
2.200
-0.42%
0.050
-41.53%
-15.80%
336.731
Biotechnology
NUVB 		Nuvation Bio Inc
84,793
273.030
-19.31%
2.060
-0.38%
0.030
-27.04%
+53.64%
776.690
Biotechnology
ERAS 		Erasca Inc
89,278
258.010
-19.31%
1.950
-0.33%
0.030
+15.52%
+38.03%
830.563
Biotechnology
FHTX 		Foghorn Therapeutics Inc
30,695
254.150
-19.30%
1.920
-0.26%
0.060
+59.93%
+38.60%
494.638
Biotechnology
RVMD 		Revolution Medicines Inc
5,810
247.680
-19.26%
1.870
-0.32%
0.000
+33.59%
+97.87%
9479.460
Biotechnology

Range Cancer Therapeutics ETF's Historical Top Holdings Breakdowns

Range Cancer Therapeutics ETF's Top Stock Picks View Full List
Ticker
Company
Date
Action
Impact %
Price Range
Price
Price Change from Avrg%
Comment
Current Shares
Share Change
DCPH Deciphera Pharmaceuticals Inc2024-08-31Sold Out
-2.24%
●
25.55 ($25.57) 25.59
$25.59
0.08%
Sold Out
0
-14,464
MOR 		MorphoSys AG2024-08-31Sold Out
-1.43%
●
17.87 ($18.41) 19.03
$18.96
2.99%
Sold Out
0
-12,828
GERN 		Geron Corp2024-08-31Reduce
-0.55%
●
3.83 ($4.57) 5.09
$4.22
-7.66%
Reduce -19.31%
106,113
-25,387
ELVN 		Enliven Therapeutics Inc2024-08-31Reduce
-0.53%
●
20.2 ($22.76) 27.31
$28.01
23.07%
Reduce -19.3%
16,094
-3,848
SMMT 		Summit Therapeutics Inc2024-08-31Reduce
-0.49%
●
6.89 ($9.7) 13.52
$20.39
110.21%
Reduce -19.31%
39,094
-9,354
ITOS 		ITeos Therapeutics Inc2024-08-31Reduce
-0.42%
●
14.02 ($16.08) 17.97
$9.22
-42.66%
Reduce -19.3%
17,308
-4,139
ACRV 		Acrivon Therapeutics Inc2024-08-31Reduce
-0.41%
●
5.76 ($7.57) 9.98
$7.83
3.43%
Reduce -19.31%
36,627
-8,763
JANX 		Janux Therapeutics Inc2024-08-31Reduce
-0.38%
●
35.29 ($42.34) 54.98
$55.28
30.56%
Reduce -19.3%
4,917
-1,176
NUVB 		Nuvation Bio Inc2024-08-31Reduce
-0.38%
●
2.61 ($3.08) 3.83
$2.32
-24.68%
Reduce -19.31%
84,793
-20,287
CGEM 		Cullinan Therapeutics Inc2024-08-31Reduce
-0.37%
●
16.03 ($18.41) 23.25
$15.98
-13.20%
Reduce -19.3%
10,983
-2,626

Range Cancer Therapeutics ETF Total Holding History ($B)

To

Range Cancer Therapeutics ETF's Asset Allocation

To

Range Cancer Therapeutics ETF Past Portfolios

Portfolio Date Number of Stocks New Stocks Total Value ($Mil) Q/Q Turnover

Top Ranked Articles

  • 1

Range Cancer Therapeutics ETF's Hypothetical Growth since 2024-08-31

Range Cancer Therapeutics ETF's Yearly Returns

Year Portfolio % % Excess Gain %

Range Cancer Therapeutics ETF's Holdings Heat Map

Size field:

Range Cancer Therapeutics ETF's Holdings Bubble Chart

Range Cancer Therapeutics ETF News

  • 1

Discussions on Range Cancer Therapeutics ETF

User's Avatar
How would you rate this stock? CNCR
No discussions yet.
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.